Occurrence, presentation and treatment of candidemia

References

• Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348(16), 1546–1554 (2003).
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309–317 (2004).
   PubMed Web of Science ®Google Scholar
• Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int. J. Antimicrob. Agents 32(Suppl. 2), S87–S91 (2008).
   PubMed Web of Science ®Google Scholar
• Bouza E, Perez-Molina J, Munoz P. Report of ESGNI01 and ESGNI02 studies. Bloodstream infections in Europe. Clin. Microbiol. Infect. 5(Suppl. 2), 2S1–2S12 (1999).
   Google Scholar
• Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 39(4), 665–670 (2011).
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35(5), 627–630 (2002).
   PubMed Web of Science ®Google Scholar
• Blot S, Vandewoude K. Management of invasive candidiasis in critically ill patients. Drugs 64(19), 2159–2175 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181(1), 309–316 (2000).
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Jarvis WR, Soucie JM et al.; National Epidemiology of Mycoses Survey(NEMIS) Study Group. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study: the National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33(2), 177–186 (2001).
   PubMed Web of Science ®Google Scholar
• Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol. 21(8), 510–515 (2000).
   PubMed Web of Science ®Google Scholar
• Bougnoux ME, Kac G, Aegerter P, d’Enfert C, Fagon JY; CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 34(2), 292–299 (2008).
   PubMed Web of Science ®Google Scholar
• Leroy O, Gangneux JP, Montravers P et al.; AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit. Care Med. 37(5), 1612–1618 (2009).
   PubMed Web of Science ®Google Scholar
• Marriott DJ, Playford EG, Chen S et al.; Australian Candidaemia Study. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit. Care 13(4), R115 (2009).
   Google Scholar
• Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS ONE 6(9), e24198 (2011).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41(9), 1232–1239 (2005).
   PubMed Web of Science ®Google Scholar
• Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 26(6), 540–547 (2005).
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37(9), 1172–1177 (2003).
   PubMed Web of Science ®Google Scholar
• Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48(12), 1695–1703 (2009).
   PubMed Web of Science ®Google Scholar
• Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15(3), 414–421 (1992).
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Peacock JE Jr, Tanner DC et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch. Intern. Med. 155(22), 2429–2435 (1995).
   PubMed Web of Science ®Google Scholar
• Nucci M, Colombo AL, Silveira F et al. Risk factors for death in patients with candidemia. Infect. Control Hosp. Epidemiol. 19(11), 846–850 (1998).
   PubMed Web of Science ®Google Scholar
• Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am. J. Med. 113(6), 480–485 (2002).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. 40(4), 1298–1302 (2002).
   PubMed Web of Science ®Google Scholar
• Passos XS, Costa CR, Araújo CR et al. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia 163(3), 145–151 (2007).
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lazarus DR, Sherner JH et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit. Care Med. 35(4), 1077–1083 (2007).
   PubMedGoogle Scholar
• Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect. Dis. 6, 21 (2006).
   PubMed Web of Science ®Google Scholar
• Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin. Infect. Dis. 46(8), 1206–1213 (2008).
   PubMed Web of Science ®Google Scholar
• Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112(11), 2493–2499 (2008).
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Peman J, Bernhardt H et al.; ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23(4), 317–322 (2004).
   PubMed Web of Science ®Google Scholar
• Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin. Infect. Dis. 39(Suppl. 4), S185–S192 (2004).
   Google Scholar
• Pereira GH, Muller PR, Szeszs MW, Levin AS, Melhem MS. Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med. Mycol. 48, 839–842 (2010).
   PubMed Web of Science ®Google Scholar
• Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int. J. Infect. Dis. 15(11), e759–e763 (2011).
   PubMed Web of Science ®Google Scholar
• Ortega M, Marco F, Soriano A et al. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J. Hosp. Infect. 77(2), 157–161 (2011).
   PubMed Web of Science ®Google Scholar
• Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50(4), 243–260 (2002).
   PubMed Web of Science ®Google Scholar
• Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. Candida glabrata fungaemia in intensive care units. Clin. Microbiol. Infect. 14(2), 136–140 (2008).
   PubMedGoogle Scholar
• Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int. J. Infect. Dis. 14(11), e954–e966 (2010).
   PubMed Web of Science ®Google Scholar
• Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth. Analg. 106(2), 523–529, table of contents (2008).
   PubMed Web of Science ®Google Scholar
• Cohen Y, Karoubi P, Adrie C et al. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit. Care Med. 38(3), 826–830 (2010).
   PubMed Web of Science ®Google Scholar
• Hernández-Castro R, Arroyo-Escalante S, Carrillo-Casas EM et al. Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur. J. Pediatr. 169(7), 783–787 (2010).
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida albicans: an epidemiologic study. J. Infect. Dis. 168(1), 195–201 (1993).
   PubMed Web of Science ®Google Scholar
• Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch. Intern. Med. 149(10), 2349–2353 (1989).
   PubMed Web of Science ®Google Scholar
• Mikulska M, Bassetti M, Ratto S, Viscoli C. Invasive candidiasis in non-hematological patients. Mediterr. J. Hematol. Infect. Dis. 3(1), e2011007 (2011).
   Google Scholar
• Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28(5), 1071–1079 (1999).
   PubMed Web of Science ®Google Scholar
• Blot S, Janssens R, Claeys G et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J. Antimicrob. Chemother. 58(2), 474–477 (2006).
   PubMedGoogle Scholar
• Fournier P, Schwebel C, Maubon D et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J. Antimicrob. Chemother. 66(12), 2880–2886 (2011).
   PubMed Web of Science ®Google Scholar
• Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J. Hosp. Infect. 50(1), 56–65 (2002).
   PubMed Web of Science ®Google Scholar
• Holley A, Dulhunty J, Blot S et al. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int. J. Antimicrob. Agents 33(6), 554.e1–554.e7 (2009).
   Google Scholar
• Ha JF, Italiano CM, Heath CH, Shih S, Rea S, Wood FM. Candidemia and invasive candidiasis: a review of the literature for the burns surgeon. Burns 37(2), 181–195 (2011).
   PubMed Web of Science ®Google Scholar
• Blot S, Vandewoude K, Hoste E, Poelaert J, Colardyn F. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. J. Hosp. Infect. 47(4), 308–313 (2001).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D et al.; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48(5), 503–535 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int. J. Antimicrob. Agents 38(1), 65–69 (2011).
   PubMed Web of Science ®Google Scholar
• Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35(3), 211–218 (2010).
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D et al. Candida spp. with Acquired Echinocandin Resistance, France, 2004–2010(1). Emerg. Infect. Dis. 18(1), 86–90 (2010).
   Google Scholar
• Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55(2), 532–538 (2011).
   PubMed Web of Science ®Google Scholar
• Kale-Pradhan PB, Morgan G, Wilhelm SM, Johnson LB. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis infections: a meta-analysis. Pharmacotherapy 30(12), 1207–1213 (2010).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Duncanson F, Messer SA, Moet GJ, Jones RN, Castanheira M. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods. Antimicrob. Agents Chemother. 55(11), 5155–5158 (2011).
   PubMedGoogle Scholar
• Cisterna R, Ezpeleta G, Telleria O et al.; Spanish Candidemia Surveillance Group. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J. Clin. Microbiol. 48(11), 4200–4206 (2010).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13(6), 180–195 (2010).
   PubMed Web of Science ®Google Scholar
• Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg. 220(6), 751–758 (1994).
   PubMed Web of Science ®Google Scholar
• Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit. Care Med. 31(3), 752–757 (2003).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 26(4), 271–276 (2007).
   PubMed Web of Science ®Google Scholar
• León C, Ruiz-Santana S, Saavedra P et al.; EPCAN Study Group. A bedside scoring system (‘Candida score’) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit. Care Med. 34(3), 730–737 (2006).
   PubMed Web of Science ®Google Scholar
• León C, Ruiz-Santana S, Saavedra P et al.; Cava Study Group. Usefulness of the ‘Candida score’ for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit. Care Med. 37(5), 1624–1633 (2009).
   PubMed Web of Science ®Google Scholar
• Leroy G, Lambiotte F, Thévenin D et al. Evaluation of ‘Candida score’ in critically ill patients: a prospective, multicenter, observational, cohort study. Ann. Intensive Care 1(1), 50 (2011).
   PubMedGoogle Scholar
• Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn. Microbiol. Infect. Dis. 17(2), 103–109 (1993).
   PubMed Web of Science ®Google Scholar
• Horvath LL, Hospenthal DR, Murray CK, Dooley DP. Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles. J. Clin. Microbiol. 41(10), 4714–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Lai CC, Wang CY, Liu WL, Huang YT, Hsueh PR. Time to blood culture positivity of different Candida species causing fungemia. J. Med. Microbiol. 61, 701–704 (2012).
   PubMed Web of Science ®Google Scholar
• Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C; Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit. Care 14(6), R222 (2010).
   Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46(12), 1813–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S; European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 47(6), 846–854 (2012).
   PubMed Web of Science ®Google Scholar
• Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1,3)-β-d-glucan serum concentrations in long-term intensive care patients. Int. J. Infect. Dis. 13(6), 707–712 (2009).
   PubMed Web of Science ®Google Scholar
• Lamoth F, Cruciani M, Mengoli C et al.; Third European Conference on Infections in Leukemia (ECIL-3). b-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin. Infect. Dis. 54(5), 633–643 (2012).
   PubMed Web of Science ®Google Scholar
• Del Bono V, Mularoni A, Furfaro E et al. Clinical evaluation of a (1,3)-β-d-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin. Vaccine Immunol. 16(10), 1524–1526 (2009).
   PubMedGoogle Scholar
• Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. ß-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin. Infect. Dis. 52(6), 750–770 (2011).
   PubMed Web of Science ®Google Scholar
• Onishi A, Sugiyama D, Kogata Y et al. Diagnostic accuracy of serum 1,3-ß-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J. Clin. Microbiol. 50(1), 7–15 (2012).
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen YQ, Guo YL, Qin SM, Wu C, Wang K. Diagnosis of invasive fungal disease using serum (1?3)-ß-D-glucan: a bivariate meta-analysis. Intern. Med. 50(22), 2783–2791 (2011).
   PubMed Web of Science ®Google Scholar
• Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J. Clin. Microbiol. 49(2), 665–670 (2011).
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Wissel MC, Shields RK et al. Performance of Candida real-time polymerase chain reaction, ß-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin. Infect. Dis. 54(9), 1240–1248 (2012).
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49(9), 3640–3645 (2005).
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43(1), 25–31 (2006).
   PubMed Web of Science ®Google Scholar
• Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60(3), 613–618 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit. Care Med. 31(7), 1938–1946 (2003).
   PubMed Web of Science ®Google Scholar
• Sandven P, Qvist H, Skovlund E, Giercksky KE; NORGAS Group and the Norwegian Yeast Study Group. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit. Care Med. 30(3), 541–547 (2002).
   PubMed Web of Science ®Google Scholar
• He YM, Lv XS, Ai ZL et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World J. Gastroenterol. 9(11), 2619–2621 (2003).
   PubMed Web of Science ®Google Scholar
• Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 28(12), 1708–1717 (2002).
   PubMed Web of Science ®Google Scholar
• Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care Med. 27(6), 1066–1072 (1999).
   PubMed Web of Science ®Google Scholar
• Lipsett PA. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin. Infect. Dis. 39(Suppl. 4), S193–S199 (2004).
   Google Scholar
• Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med. 31(11), 1479–1487 (2005).
   PubMed Web of Science ®Google Scholar
• Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit. Care Med. 33(9), 1928–1935; quiz 1936 (2005).
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J. Antimicrob. Chemother. 57(4), 628–638 (2006).
   PubMed Web of Science ®Google Scholar
• Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. 233(4), 542–548 (2001).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Ansaldi F, Nicolini L et al. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J. Antimicrob. Chemother. 64(3), 625–629 (2009).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 23(10), 739–744 (2004).
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72(1), 101–111 (1982).
   PubMed Web of Science ®Google Scholar
• Schuster MG, Edwards JE Jr, Sobel JD et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann. Intern. Med. 149(2), 83–90 (2008).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit. Care 14(6), 244 (2010).
   PubMed Web of Science ®Google Scholar
• Cornely O, Bassetti M, Calandra T et al. ESCMID guideline for the diagnosis and management of candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. doi:10.1111/1469-0691.12039 (Epub. ahead of print) (2012).
   Google Scholar
• Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit. Care 15(5), R253 (2011).
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW et al.; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54(8), 1110–1122 (2012).
   PubMed Web of Science ®Google Scholar
• Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21(4), 606–625 (2008).
   PubMed Web of Science ®Google Scholar
• Colombo AL, Ngai AL, Bourque M et al. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob. Agents Chemother. 54(5), 1864–1871 (2010).
   PubMedGoogle Scholar
• Oude Lashof AM, Rothova A, Sobel JD et al. Ocular manifestations of candidemia. Clin. Infect. Dis. 53(3), 262–268 (2011).
   PubMedGoogle Scholar
• Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49(1), 1–45 (2009).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin. Infect. Dis. 51(3), 295–303 (2010).
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin. Infect. Dis. 54(8), 1123–1125 (2012).
   PubMed Web of Science ®Google Scholar
• Öncü S. In vitro effectiveness of antifungal lock solutions on catheters infected with Candida species. J. Infect. Chemother. 17(5), 634–639 (2011).
   PubMed Web of Science ®Google Scholar
• Cateau E, Berjeaud JM, Imbert C. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int. J. Antimicrob. Agents 37(4), 380–384 (2011).
   PubMed Web of Science ®Google Scholar
• Toulet D, Debarre C, Imbert C. Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials? J. Antimicrob. Chemother. 67(2), 430–432 (2012).
   PubMed Web of Science ®Google Scholar
• Angel-Moreno A, Boronat M, Bolaños M, Carrillo A, González S, Pérez Arellano JL. Candida glabrata fungemia cured by antibiotic-lock therapy: case report and short review. J. Infect. 51(3), e85–e87 (2005).
   Google Scholar
• Johnson MD, Plantinga TS, Van De Vosse E et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin. Infect. Dis. (2011).
   Google Scholar